Computational Biology Global Market Report 2024

Computational biology refers to the field of science that teaches students how to use computer science, statistics, and mathematics to solve biological problems. A wide range of biological disciplines, including genomics/genetics, biophysics, cell biology, biochemistry, and evolution, are included in computational biology.

The main types of computational biology are in-house and contract. The in-house market consists of sales of computational biological solutions that are performed within a company. The firm uses its own employees and time to perform a business activity, such as financing or brokering. The various tools applied are databases, infrastructure (hardware), and analysis software and services that are used in applications such as cellular and biological simulation, drug discovery and disease modelling, and clinical trials. The industries that have adopted computational biology are research, the pharmaceutical industry, and commercial applications.

The computational biology market research report is one of a series of new reports that provides computational biology market statistics, including computational biology industry global market size, regional shares, competitors with a computational biology market share, detailed computational biology market segments, market trends and opportunities, and any further data you may need to thrive in the computational biology industry. This computational biology market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The computational biology market size has grown rapidly in recent years. It will grow from $6.96 billion in 2023 to $8.27 billion in 2024 at a compound annual growth rate (CAGR) of 18.8%. The growth in the historic period can be attributed to multi-omics integration, personalized medicine and precision healthcare, genomic sequencing revolution, handling biological big data.

The computational biology market size is expected to see exponential growth in the next few years. It will grow to $17.86 billion in 2028 at a compound annual growth rate (CAGR) of 21.2%. The growth in the forecast period can be attributed to cloud computing and high-performance computing (hpc), quantitative and predictive biology adoption, collaborative interdisciplinary research, advancements in bioinformatics and computational tools. Major trends in the forecast period include advancements in data science and bioinformatics, genomic sequencing technologies, machine learning and ai in bioinformatics, drug discovery and development, personalized medicine and precision healthcare.

Government funding has been the major driver in the computational biology market. Governments across the globe are funding infrastructure and academic courses to improve the capabilities of computational biologics in R&D, educational institutions, and other sectors. The rapid growth in government funding is expected to boost the demand for computational biological solutions, as they are widely used in R&D, clinical research, and other development activities. For instance, in April 2023, according to National Cancer Institute (NCI), a US-based government agency, in the fiscal year 2021, the NCI had a total budget of $6.4 billion, which included $195 million in funding from the CURES Act. This represented a 1.6 percent increase, equivalent to $99.3 million, compared to the preceding fiscal year. Therefore, government funding is driving the computational biology market growth.

The increasing demand for personalized medicine is expected to propel the growth of computational biology going forward. Personalized medicine, also known as precision medicine, is an approach to medical treatment and healthcare that takes into account individual variability in genes, environment, and lifestyle when developing treatment plans for patients. Personalized medicine relies on analyzing an individual's genetic data to tailor medical treatments. Computational biology plays a vital role in interpreting this genetic information, enabling the development of targeted therapies, optimizing treatment regimens, and predicting treatment outcomes. It helps stratify patients into specific subgroups, reduces healthcare costs, and aligns with regulatory and clinical guidelines. For instance, in 2022, according to the Personalized Medicine Coalition, a US-based professional membership organization, the Food and Drug Administration’s Center for Drug Evaluation and Research (CDER) approved 37 new molecular entities (NMEs) in 2022. Out of the 35 therapeutic NMEs, approximately 34%, which amounts to 12 of them, are classified as personalized medicines by the Personalized Medicine Coalition (PMC). Therefore, the increasing demand for personalized medicine is driving the growth of the computational biology market.

Major companies operating in the computational biology market are developing new solutions for proteomics research to gain a competitive edge in the market. Proteomics research is a field of scientific study focused on the comprehensive analysis of proteins in a biological system. For instance, in May 2023, Biognosys AG, a Switzerland-based biotechnology company launched Spectronaut 18 and unveiled significant scientific and technological enhancements for its exclusive proteomics research software and offerings. Spectronaut 18 offers high throughput and efficiency in data-independent acquisition (DIA) proteomics analysis. The company's TrueDiscovery platform accelerates biomarker discovery in fields like oncology and neuroscience by providing unparalleled depth and sensitivity in proteomics. TrueTarget enables high-resolution drug target identification and deconvolution, and Biognosys' iRT Kit, recommended for real-time system suitability monitoring, is now supported in combination with Bruker ProteoScape software.

Major companies operating in the computational biology market are developing advanced biosimulation solutions to gain a competitive edge in the market. Biosimulation software refers to a category of computer programs and tools used in the field of computational biology and pharmacology to simulate and model biological systems and processes. For instance, in June 2022, Certara, a US-based software development company launched new versions of its Immunogenicity (IG), Immuno-oncology (IO), and Vaccine Simulators to enhance the predictability of novel biologic therapies in drug development. These simulators are built on quantitative systems pharmacology (QSP) and use computational modeling and experimental data to understand drug interactions with biological systems and disease processes. They assist in creating virtual patients, conducting computer-based trials, and predicting drug behavior in patients, streamlining the drug development process and minimizing risks. Certara's IG Simulator assesses immunogenicity in various biologic therapies, the IO Simulator optimizes cancer therapy combinations, and the Vaccine Simulator determines vaccine dosing strategies.

In March 2022, ZS Associates, a US-based provider of professional services acquired Intomics for an undisclosed amount. Through this acquisition, ZS Associates is focused on diversifying their business activities and offering its clients innovative solutions. Intomics is a Denmark-based provider of bioinformatics solutions and system biology.

Major companies operating in the in the computational biology market report are Accelrys Inc., Certara L. P, Chemical Computing Group Inc., Compugen Ltd., Entelos Inc., Genedata AG, Insilico Biotechnology AG, Dassault Systèmes SE, Instem PLC, Rosa & Co. LLC, Simulation Plus Inc., Nimbus Discovery LLC, Rhenovia Pharma SAS, Leadscope Inc., DNAnexus, Altaris Capital Partner, Genialis Inc., Inari Agriculture Inc., BC Platforms, Ventus Therapeutics, Monte Rosa Therapeutics, Schrodinger Inc., Strand Life Sciences, Entos Pharmaceuticals, Numerate Inc., Insitro, Recursion Pharmaceuticals, Atomwise, Relay Therapeutics, Exscientia

North America was the largest region in the computational biology market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the computational biology market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the computational biology market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain.

The computational biology market includes revenues earned by entities by providing biological notions rigor and verifiability, as well as by offering a framework that connects diverse insights. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified)).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.